ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

June 22, 2022 | Bradley Monk, MD, FACS, FACOG

Share on:

Bradley Monk, MD, FACS, FACOG, presents slides from the American Society of Clinical Oncology 2022 (ASCO) conference and discusses the use of rucaparib as maintenance treatment for ovarian cancer.